Most Download
1
Laboratory Diagnosis and Molecular Epidemiological Characterization of the First Imported Case of Lassa Fever in China
(30 day view times: 47)
2025, 38(3): 279-289.
doi: 10.3967/bes2025.014
2
Report on Cardiovascular Health and Diseases in China 2022: an Updated Summary
(30 day view times: 34)
2023, 36(8): 669-701.
doi: 10.3967/bes2023.106
In the past 30 years, the accessibility and quality index of medical care have made remarkable progress in China, ranking the first among middle-income countries. Many cardiovascular technologies are at or near the world's leading level, and significant progress has been achieved in China solving the problem of “treatment difficulty” of cardiovascular diseases (CVD). However, due to the prevalence of unhealthy lifestyles among Chinese residents, a huge population with CVD risk factors, accelerated population aging, and other reasons, the incidence and mortality rate of CVD are still increasing, and the turning point of the decline in disease burden has not appeared yet in China. In terms of proportions of disease mortality among urban and rural residents, CVD still ranks the first. In 2020, CVD accounted for 48.00% and 45.86% of the causes of death in rural and urban areas, respectively; two out of every five deaths were due to CVD. It is estimated that the number of current CVD patients in China is around 330 million, including 13 million stroke, 11.39 million coronary heart disease, 8.9 million heart failure, 5 million pulmonary heart disease, 4.87 million atrial fibrillation, 2.5 million rheumatic heart disease, 2 million congenital heart disease, 45.3 million peripheral artery disease, and 245 million hypertension cases. China has entered a new stage of transformation from high-speed development to high-quality development, and the prevention and control of CVD in China should also shift from previous emphasis on scale growth to strategies focusing more on strategic and key technological development in order to curb the trend of increasing incidence and mortality rates of CVD.
3
Environmental Temperature and the Risk of Hand, Foot, and Mouth Disease Transmission in the Yangtze River Region of China
(30 day view times: 29)
2025, 38(3): 290-302.
doi: 10.3967/bes2025.011
4
Causal Associations between Particulate Matter 2.5 (PM2.5), PM2.5 Absorbance, and Inflammatory Bowel Disease Risk: Evidence from a Two-Sample Mendelian Randomization Study
(30 day view times: 29)
2025, 38(2): 167-177.
doi: 10.3967/bes2024.142
5
Association of Loneliness and Social Isolation with Ischemic Heart Disease: A Bidirectional and Network Mendelian Randomization Study
(30 day view times: 24)
2025, 38(3): 351-364.
doi: 10.3967/bes2024.170
6
The First Imported Case of Lassa Fever in China – Implications for Global Health Surveillance
(30 day view times: 24)
2025, 38(3): 277-278.
doi: 10.3967/bes2025.029
7
Mito-TEMPO Ameliorates Sodium Palmitate Induced Ferroptosis in MIN6 Cells through PINK1/Parkin-Mediated Mitophagy
(30 day view times: 23)
2024, 37(10): 1128-1141.
doi: 10.3967/bes2024.111
8
Impact of Laboratory Analytical Indicators on Positive Blood Culture Detection Rates: A Single Center Study
(30 day view times: 23)
2025, 38(3): 303-312.
doi: 10.3967/bes2024.157
10
Research Advances in the Construction and Application of Intestinal Organoids
(30 day view times: 22)
2025, 38(2): 230-247.
doi: 10.3967/bes2025.010
The structure of intestinal tissue is complex. In vitro simulation of intestinal structure and function is important for studying intestinal development and diseases. Recently, organoids have been successfully constructed and they have come to play an important role in biomedical research. Organoids are miniaturized three-dimensional (3D) organs, derived from stem cells, which mimic the structure, cell types, and physiological functions of an organ, making them robust models for biomedical research. Intestinal organoids are 3D micro-organs derived from intestinal stem cells or pluripotent stem cells that can successfully simulate the complex structure and function of the intestine, thereby providing a valuable platform for intestinal development and disease research. In this article, we review the latest progress in the construction and application of intestinal organoids.
11
Trends of Disease Burden of Pancreatic Cancer Attributed to High Fasting Plasma Glucose in China,1990–2021: Insights from the Global Burden of Disease Study 2021
(30 day view times: 22)
2025, 38(3): 379-384.
doi: 10.3967/bes2025.027
12
A New Classification System for Childhood and Adolescent Obesity: Definition of the BCAMS Classification
(30 day view times: 21)
2025, 38(3): 376-378.
doi: 10.3967/bes2025.006
13
Impact of Endometrial Polyps on Pregnancy Outcomes in Patients with Endometriosis and Infertility: A Systematic Review and Meta-analysis
(30 day view times: 21)
2025, 38(3): 341-350.
doi: 10.3967/bes2024.175
14
Comprehensive Analysis of Oncogenic, Prognostic, and Immunological Roles of FANCD2 in Hepatocellular Carcinoma: A Potential Predictor for Survival and Immunotherapy
(30 day view times: 21)
2025, 38(3): 313-327.
doi: 10.3967/bes2024.182
15
Advancements in Mpox Vaccine Development: A Comprehensive Review of Global Progress and Recent Data
(30 day view times: 20)
2025, 38(2): 248-254.
doi: 10.3967/bes2024.121
Since May 2022, a severe global Mpox epidemic has underscored the urgent need for a preventative vaccine. On September 16, 2022, the mainland of China reported its first case of imported Mpox, which was subsequently followed by a significant rise in domestic infections commencing from June 2023. This alarming trend has escalated the likelihood of localized outbreaks and covert transmission, posing a heightened risk to public health. Notably, the United States, many European countries, and Japan have approved the use of smallpox vaccines for Mpox prevention and emergency vaccination post-exposure, based on their cross-protection efficacy. In recent years, virology research has broadened its scope to include investigations into various novel vaccine approaches, such as nucleic acid-based vaccines, protein subunit vaccines, and epitope peptide vaccines, and other related methodologies. This review offers a thorough examination of the current global landscape of Mpox prevalence, delves into the advancements in Mpox vaccine development, and highlights the progress achieved in Mpox vaccine research, serving as a valuable resource and providing technical insights essential for the effective prevention and control of Mpox.
16
Bone Injury and Fracture Healing Biology
(30 day view times: 20)
2015, 28(1): 57-71.
doi: 10.3967/bes2015.006
17
Traditional Chinese Medicine Treatment, Gua Sha, can Induce Subtle Molecular Changes in Gene Expression
(30 day view times: 19)
2023, 36(5): 441-451.
doi: 10.3967/bes2023.053
18
Therapeutic Strategies for Tuberculosis: Progress and Lessons Learned
(30 day view times: 17)
2024, 37(11): 1310-1323.
doi: 10.3967/bes2024.168
Tuberculosis (TB) remains a significant global health challenge, ranking second only to COVID-19 as the leading cause of death from a single infectious agent, with 1.3 million TB-related deaths reported in 2022. Treatment efficacy has been compromised by the emergence of drug-resistant strains, including rifampin-resistant TB (RR-TB), multidrug-resistant TB (MDR-TB), and extensively drug-resistant TB (XDR-TB). Although first-line drugs like isoniazid, rifampicin, pyrazinamide, and ethambutol form the cornerstone of TB therapy, the rise of resistant strains necessitates the use of second-line drugs, which often come with increased toxicity and limited accessibility. Recent advances have focused on repurposing existing compounds and developing new drugs with novel mechanisms of action. Promising agents such as second-generation bedaquiline analogs (TBAJ-587, TBAJ-876), sudapyridine (WX-081), delamanid, pretomanid, and TBI-166 (pyrifazimine) have shown efficacy against resistant Mtb strains. Innovative treatment regimens like the BPaLM protocol—combining bedaquiline, pretomanid, linezolid, and moxifloxacin—offer shorter, all-oral therapies with higher cure rates. Personalized treatment durations and dose optimizations are becoming feasible through risk stratification algorithms and pharmacokinetic/pharmacodynamic studies. Immunotherapy is emerging as a complementary strategy to enhance the host’s immune response against Mtb. Agents such as vitamin D, corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), statins, metformin, and biological agents like interleukins and granulocyte-macrophage colony-stimulating factor are under exploration. Additionally, cell therapies involving mesenchymal stem cells and immune effector cells present new therapeutic avenues. Despite these advancements, significant challenges remain in achieving the World Health Organization’s “End TB Strategy” goals, particularly as the COVID-19 pandemic has diverted resources and attention. Ongoing research and global collaboration are crucial to develop novel therapeutic strategies, optimize treatment regimens, and ultimately reduce the global burden of TB.
19
Dietary Guide for Hyperuricemia and Gout Patients (WS/T 560—2017)
(30 day view times: 17)
2023, 36(9): 897-898.
doi: 10.3967/bes2023.118
20
Correlation between Anxiety, Depression, and Sleep Quality in College Students
(30 day view times: 15)
2022, 35(7): 648-651.
doi: 10.3967/bes2022.084